Rechtsfragen
Querschnittsansicht der Rechtsgrundsätze, wiederkehrender Argumente und des Stands der Technik, auf den sich das Gericht stützt.
Meistdiskutierte Rechtsgrundsätze
Wiederkehrende Rechtsgrundsätze über 1 Fälle mit extrahierter Begründung. Die Erfolgsquote zählt patenthalterfreundliche Ausgänge.
Häufigste zurückgewiesene Argumente
Argumente, die das UPC nicht akzeptiert hat, sortiert nach wiederholten Auftritten in Fällen.
| Argument | Partei | Fälle |
|---|---|---|
| preliminary cost reimbursement order should be granted in preliminary injunction proceedings | Kläger | 1 |
| validity attacks (best three arguments) defeat the patent at pi stage | Beklagter | 1 |
| huawei's claims are barred by ieee bylaws / letter of assurance commitments (prohibition on suit) | Beklagter | 1 |
| exhaustion defence applies to all accused product variants | Beklagter | 1 |
| stay of infringement proceedings warranted because central division paris decision was manifestly and prima facie erroneous for failing to consider key invalidity arguments | Beklagter | 1 |
| patent ep 3 646 825 is invalid (counterclaim for revocation) | Beklagter | 1 |
| direct infringement of device claim established because defendant appropriates downstream customer acts (verlängerte werkbank / extended workbench theory) | Kläger | 1 |
| patent ep 3 866 051 is invalid (validity challenge in pi proceedings) | Beklagter | 1 |
| application for seizure of goods should be maintained in full | Kläger | 1 |
| d7 (new prior art) submitted with written submission of 15 march 2024 admitted to revocation proceedings | Beklagter | 1 |
| revocation counterclaims — patent invalid | Beklagter | 1 |
| ep 3 350 592 as granted is valid | Kläger | 1 |
| auxiliary requests 1 and 2 are valid | Kläger | 1 |
| auxiliary requests for provisional measures based on amended claim versions should be admitted | Kläger | 1 |
| preliminary cost reimbursement of eur 168,000 should be granted to respondent | Beklagter | 1 |
| applications to amend the patent (auxiliary requests) should cure the added-matter defect | Beklagter | 1 |
| claims 1 and 11 of ep 3 972 309 are infringed by asus devices | Kläger | 1 |
| aorticlab's device infringes ep 2 129 425 because irregular patent-compliant use by medical professionals constitutes infringement | Kläger | 1 |
| private prior use right (in de, fr, it, ro) precludes infringement finding | Beklagter | 1 |
| invalidity of ep 2 839 083 b9 as originally granted (revocation counterclaim) | Beklagter | 1 |
| infringement is impossible due to features outside the patent claim that prevent the patented function from being achieved | Beklagter | 1 |
| claims 1 and 11 are supported by the parent application and do not go beyond its content | Kläger | 1 |
| auxiliary requests to amend the patent should cure the added-matter defect | Kläger | 1 |
| ep 2 493 466 (cabazitaxel antitumour use patent) is valid over the prior art | Kläger | 1 |
| no auxiliary requests for patent amendment filed | Kläger | 1 |
Meistzitierter Stand der Technik
Über substanzielle Hauptsachefälle herangezogene Schriften und ihre typische Rolle.
| Schriftreferenz | Vorherrschende Rolle | Fälle |
|---|---|---|
| Levi (Exhibit HLNK 39) | Erfindungsmüh-Kombination | 1 |
| Alon (Exhibit HLNK 49) | Erfindungsmüh-Kombination | 1 |
| Fontaine (Exhibit HLNK 25) | Erfindungsmüh-Kombination | 1 |
| EP 3 583 920 B1 (family member) | Hintergrund | 1 |
| D7 (unspecified late-filed document) | Erfindungsmüh-Kombination | 1 |
| NHSC document (clinical/regulatory document disclosing cabazitaxel antitumour use in docetaxel-pretreated patients) | Neuheitsschädlich | 1 |
| prior public use / offenkundige Vorbenutzung of sintered metal preparation by Vibrantz | Neuheitsschädlich | 1 |
| ZP8-ZP9 (late-filed documents admitted in response to AR1-24) | Erfindungsmüh-Kombination | 1 |
| D3 | Neuheitsschädlich | 1 |